- InMode’s second-quarter revenue was $95.6 million, marking an 11% increase year-over-year, but it missed the estimated $96.9 million.
- The company’s adjusted earnings per share (EPS) rose to 47 cents compared to 34 cents last year, beating the estimate of 41 cents.
- Gross margin remained steady at 80% year-over-year.
- External challenges, such as macroeconomic uncertainty and cautious consumer behavior, affected the quarter’s performance.
- International business helped offset some of the negative impacts from economic challenges in the U.S.
- U.S. tariffs at current levels are expected to reduce gross margins by approximately 2% to 3%.
- Analyst recommendations include 1 buy, 6 holds, and 0 sells.
A look at Inmode Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Investment analysts have assessed Inmode’s long-term outlook using the Smartkarma Smart Scores, a comprehensive tool indicating various aspects of the company’s performance. Inmode received a high score for Resilience, highlighting its ability to navigate challenges and maintain stability in the face of market fluctuations. Additionally, the company scored well in Value, implying that it may be considered undervalued compared to its intrinsic worth. While Growth scored moderately, there is room for expansion and development. On the other hand, Inmode scored low in Dividend and Momentum, indicating less emphasis on dividend payouts and a slower pace of market performance.
Overall, Inmode, a company specializing in developing medical devices utilizing innovative radio-frequency technology, shows promising signs for long-term sustainability and value growth. With a strong emphasis on resilience and a solid foundation for value, Inmode may weather market uncertainties and potentially offer future growth opportunities. As the company continues to expand its global customer base, there is potential for further market penetration and innovation in the medical device industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
